Oxford Immunotec develops immunology-focused diagnostic tests based on its patented T‑SPOT technology, with its primary product being the T‑SPOT.TB test for latent tuberculosis. The company runs testing laboratory operations in both the US and the UK (Oxford Diagnostic Laboratories) and sells tests in kit form. T‑SPOT.TB is described as the first FDA‑approved method for directly quantifying antigen-specific T cells and has regulatory approval in over 40 countries. In the US the T‑SPOT.TB test has CPT code 86481 and recently increased CMS reimbursement of approximately $106 per test. The company intends to use new funding to expand sales and marketing for the T‑SPOT.TB test and to accelerate development and commercialization of additional infectious and immunological assays. Management highlights the market opportunity for latent TB testing and the company’s lab‑based US business model as drivers of growth. Oxford Immunotec develops and commercializes T cell–based diagnostic tests, most notably the laboratory-based T‑SPOT®.TB cellular blood test that diagnoses latent and active tuberculosis by measuring MTB‑specific T cells. The company is advancing its diagnostic product pipeline and using new capital to support ongoing commercialization of T‑SPOT®.TB. T‑SPOT®.TB is currently marketed in the United States, Europe, Canada and more than 40 other countries worldwide. Oxford Immunotec is based in Oxford, UK, with U.S. operations in Marlborough, MA. The company recently closed the second tranche of a $26M Series D financing to fund these activities.

Total raised

$54M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2012